Special Issue "Virus Neutralizing and Enhancing Antibodies"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: 28 February 2022.

Special Issue Editor

Dr. Surender Khurana
E-Mail Website
Guest Editor
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA
Interests: immunity; influenza; vaccine modalities

Special Issue Information

Dear Colleagues,

Diseases caused by viral pathogens remains a global public health challenge. Therefore, development of effective vaccines and therapeutics for viruses including SARS-CoV-2 is a high global priority. Current vaccines provide variable immunity against emerging viruses, precluding effective stockpiling and may require yearly vaccination. While both humoral and cellular immunity plays a role in protection against viruses, current vaccines evaluate antibody as surrogate readouts for vaccine immunogenicity and efficacy. During infection, viruses induce the production of antibodies differing in their isotype, neutralization capacity, breadth of neutralization, recognition of surface versus internal viral proteins, epitope specificity, and overall structure. Despite recent advancements in the characterization of antibody responses to a number of multiple viral pathogens including SARS-CoV-2, Ebola, Zika, Influenza, RSV, HIV, at both molecular and epidemiological levels, critical knowledge gaps still exist.

Therefore, there is need to perform in-depth to understand antibody responses following vaccination and infection. It may facilitate development and evaluation of vaccine and therapeutics against virus. 

This Special Issue of Vaccines aims at addressing the unresolved key issues that hamper our understanding of the interactions between viruses and antibodies. The new presented studies will shed light on the multifaceted biological role that antibodies play during the course of virus infections. Both original research and review articles are welcome. Potential topics include, but are not limited to: 

  • Antigenic evolution and immunity to virus;
  • Antibody and human cellular immune cell responses;
  • Broadly cross-reactive and universal immunity to virus;
  • Antigens and antibody in pathogenesis of viral infections;
  • Dynamics of the antibody response during viral infections. 
  • We look forward to receiving your interested contribution.

Dr. Surender Khurana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • neutralization
  • antibody-dependent enhancement
  • vaccine efficacy
  • therapeutic antibodies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Overview of Neutralizing Antibodies and Their Potential in COVID-19
Vaccines 2021, 9(12), 1376; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9121376 - 23 Nov 2021
Cited by 1 | Viewed by 683
Abstract
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity [...] Read more.
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19. Full article
(This article belongs to the Special Issue Virus Neutralizing and Enhancing Antibodies)
Show Figures

Figure 1

Back to TopTop